| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Aneurysm, Thoracic | 142 | 2026 | 699 | 18.200 |
Why?
|
| Blood Vessel Prosthesis Implantation | 72 | 2026 | 758 | 8.400 |
Why?
|
| Aortic Aneurysm | 39 | 2025 | 224 | 8.250 |
Why?
|
| Aorta, Thoracic | 68 | 2025 | 527 | 7.590 |
Why?
|
| Aortic Aneurysm, Abdominal | 41 | 2025 | 367 | 6.240 |
Why?
|
| Marfan Syndrome | 36 | 2026 | 147 | 5.640 |
Why?
|
| Aorta | 35 | 2025 | 523 | 4.770 |
Why?
|
| Aortic Rupture | 20 | 2026 | 112 | 4.220 |
Why?
|
| Aortic Diseases | 26 | 2025 | 187 | 3.790 |
Why?
|
| Vascular Surgical Procedures | 33 | 2023 | 535 | 3.370 |
Why?
|
| Endovascular Procedures | 20 | 2026 | 783 | 3.330 |
Why?
|
| Postoperative Complications | 81 | 2026 | 3123 | 3.210 |
Why?
|
| Blood Vessel Prosthesis | 28 | 2026 | 481 | 2.960 |
Why?
|
| Aorta, Abdominal | 14 | 2020 | 95 | 2.540 |
Why?
|
| Aortic Valve | 18 | 2026 | 458 | 2.450 |
Why?
|
| General Surgery | 9 | 2021 | 224 | 2.200 |
Why?
|
| Ciprofloxacin | 3 | 2026 | 65 | 2.120 |
Why?
|
| Biomedical Research | 11 | 2023 | 561 | 1.930 |
Why?
|
| Specialties, Surgical | 6 | 2021 | 90 | 1.870 |
Why?
|
| Middle Aged | 167 | 2026 | 28408 | 1.850 |
Why?
|
| Editorial Policies | 6 | 2021 | 49 | 1.820 |
Why?
|
| Aged | 138 | 2026 | 20885 | 1.800 |
Why?
|
| Treatment Outcome | 101 | 2026 | 12846 | 1.790 |
Why?
|
| Male | 207 | 2026 | 64613 | 1.680 |
Why?
|
| Humans | 301 | 2026 | 130534 | 1.680 |
Why?
|
| Publishing | 4 | 2021 | 105 | 1.670 |
Why?
|
| Device Removal | 5 | 2026 | 225 | 1.670 |
Why?
|
| Myocytes, Smooth Muscle | 17 | 2025 | 171 | 1.630 |
Why?
|
| Periodicals as Topic | 7 | 2021 | 182 | 1.590 |
Why?
|
| Muscle, Smooth, Vascular | 13 | 2021 | 224 | 1.570 |
Why?
|
| Retrospective Studies | 101 | 2026 | 17634 | 1.490 |
Why?
|
| Time Factors | 57 | 2026 | 6175 | 1.480 |
Why?
|
| Female | 194 | 2026 | 70545 | 1.470 |
Why?
|
| Receptors, Transforming Growth Factor beta | 6 | 2021 | 111 | 1.460 |
Why?
|
| Coronary Artery Bypass | 23 | 2020 | 514 | 1.430 |
Why?
|
| Ehlers-Danlos Syndrome | 4 | 2026 | 52 | 1.420 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2026 | 150 | 1.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 14 | 2019 | 425 | 1.350 |
Why?
|
| Reoperation | 23 | 2026 | 815 | 1.290 |
Why?
|
| Angiotensin II | 10 | 2025 | 131 | 1.260 |
Why?
|
| Risk Factors | 71 | 2026 | 11013 | 1.250 |
Why?
|
| Inflammasomes | 4 | 2021 | 154 | 1.190 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2020 | 127 | 1.170 |
Why?
|
| Axillary Artery | 3 | 2022 | 31 | 1.160 |
Why?
|
| Hospital Mortality | 22 | 2019 | 1059 | 1.150 |
Why?
|
| Risk Assessment | 38 | 2025 | 3685 | 1.100 |
Why?
|
| Matrix Metalloproteinases | 4 | 2020 | 62 | 1.070 |
Why?
|
| Surgeons | 6 | 2023 | 289 | 1.070 |
Why?
|
| Aortography | 11 | 2021 | 153 | 1.040 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2020 | 105 | 1.040 |
Why?
|
| Paraplegia | 14 | 2024 | 84 | 1.030 |
Why?
|
| Cardiovascular Surgical Procedures | 3 | 2012 | 42 | 0.980 |
Why?
|
| Registries | 20 | 2022 | 1614 | 0.960 |
Why?
|
| Tissue Adhesives | 4 | 2009 | 39 | 0.940 |
Why?
|
| Heart Valve Diseases | 7 | 2019 | 165 | 0.930 |
Why?
|
| Fibrillin-1 | 8 | 2025 | 59 | 0.910 |
Why?
|
| Adult | 85 | 2026 | 31114 | 0.890 |
Why?
|
| Vascular Remodeling | 4 | 2025 | 46 | 0.890 |
Why?
|
| Fluoroquinolones | 3 | 2021 | 94 | 0.860 |
Why?
|
| Kidney | 4 | 2018 | 1280 | 0.860 |
Why?
|
| Thoracic Surgery | 7 | 2022 | 163 | 0.840 |
Why?
|
| Disease Models, Animal | 17 | 2026 | 4648 | 0.840 |
Why?
|
| Stents | 12 | 2022 | 788 | 0.840 |
Why?
|
| Caspase 1 | 3 | 2021 | 50 | 0.830 |
Why?
|
| Loeys-Dietz Syndrome | 5 | 2025 | 43 | 0.810 |
Why?
|
| Heart Arrest, Induced | 6 | 2017 | 75 | 0.810 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2022 | 480 | 0.810 |
Why?
|
| Heart Bypass, Left | 8 | 2011 | 15 | 0.810 |
Why?
|
| Mice, Inbred C57BL | 18 | 2025 | 4700 | 0.800 |
Why?
|
| Aneurysm, False | 6 | 2010 | 85 | 0.790 |
Why?
|
| Anti-Bacterial Agents | 4 | 2026 | 2579 | 0.790 |
Why?
|
| Single-Cell Analysis | 3 | 2021 | 348 | 0.780 |
Why?
|
| Catheterization, Peripheral | 3 | 2022 | 118 | 0.780 |
Why?
|
| Fibroblasts | 8 | 2025 | 849 | 0.780 |
Why?
|
| Prosthesis-Related Infections | 6 | 2021 | 197 | 0.770 |
Why?
|
| Prospective Studies | 25 | 2026 | 6424 | 0.770 |
Why?
|
| Efficiency | 5 | 2020 | 74 | 0.760 |
Why?
|
| Extracellular Matrix | 5 | 2020 | 233 | 0.760 |
Why?
|
| Thoracotomy | 4 | 2016 | 107 | 0.710 |
Why?
|
| Contrast Media | 3 | 2025 | 476 | 0.710 |
Why?
|
| Signal Transduction | 12 | 2025 | 4664 | 0.700 |
Why?
|
| Ischemia | 7 | 2012 | 359 | 0.700 |
Why?
|
| Extracorporeal Circulation | 2 | 2012 | 49 | 0.700 |
Why?
|
| Nanoparticles | 2 | 2025 | 301 | 0.700 |
Why?
|
| Cardiac Surgical Procedures | 14 | 2022 | 1163 | 0.690 |
Why?
|
| Prosthesis Failure | 5 | 2026 | 163 | 0.680 |
Why?
|
| Stroke | 5 | 2022 | 1059 | 0.670 |
Why?
|
| Aneurysm | 3 | 2022 | 66 | 0.660 |
Why?
|
| Triiodobenzoic Acids | 1 | 2021 | 29 | 0.660 |
Why?
|
| Transforming Growth Factor beta | 4 | 2022 | 450 | 0.660 |
Why?
|
| Case-Control Studies | 14 | 2021 | 3353 | 0.660 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2020 | 31 | 0.660 |
Why?
|
| Microfilament Proteins | 6 | 2016 | 269 | 0.650 |
Why?
|
| Sulfones | 2 | 2020 | 72 | 0.650 |
Why?
|
| Follow-Up Studies | 28 | 2020 | 5187 | 0.650 |
Why?
|
| X-Ray Microtomography | 1 | 2021 | 101 | 0.640 |
Why?
|
| Patient Readmission | 3 | 2021 | 441 | 0.640 |
Why?
|
| Animals | 40 | 2026 | 33726 | 0.640 |
Why?
|
| Proteins | 4 | 2012 | 1006 | 0.630 |
Why?
|
| Disease Progression | 6 | 2025 | 2195 | 0.630 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 217 | 0.620 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2024 | 1070 | 0.620 |
Why?
|
| Mice, Knockout | 15 | 2025 | 3812 | 0.590 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2020 | 33 | 0.590 |
Why?
|
| Mice | 24 | 2026 | 18198 | 0.580 |
Why?
|
| Gene Expression Profiling | 5 | 2025 | 1800 | 0.580 |
Why?
|
| Cells, Cultured | 15 | 2025 | 2884 | 0.570 |
Why?
|
| Employee Performance Appraisal | 1 | 2018 | 12 | 0.560 |
Why?
|
| Relative Value Scales | 1 | 2018 | 13 | 0.560 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2026 | 3425 | 0.560 |
Why?
|
| Survival Rate | 25 | 2020 | 2110 | 0.550 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 2321 | 0.550 |
Why?
|
| Faculty, Medical | 2 | 2018 | 281 | 0.540 |
Why?
|
| Aged, 80 and over | 36 | 2018 | 6771 | 0.540 |
Why?
|
| Spinal Cord Ischemia | 4 | 2019 | 31 | 0.540 |
Why?
|
| Chylothorax | 1 | 2018 | 27 | 0.530 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 298 | 0.530 |
Why?
|
| Paraparesis | 3 | 2022 | 8 | 0.510 |
Why?
|
| Sternotomy | 2 | 2014 | 41 | 0.510 |
Why?
|
| Aortic Valve Stenosis | 4 | 2014 | 353 | 0.510 |
Why?
|
| Matrix Metalloproteinase 9 | 4 | 2020 | 135 | 0.500 |
Why?
|
| Motivation | 2 | 2018 | 328 | 0.500 |
Why?
|
| DNA | 6 | 2023 | 1397 | 0.500 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2014 | 20 | 0.490 |
Why?
|
| Vasoconstriction | 1 | 2017 | 94 | 0.490 |
Why?
|
| Elastin | 4 | 2021 | 32 | 0.480 |
Why?
|
| Potassium Compounds | 2 | 2008 | 7 | 0.470 |
Why?
|
| Cardioplegic Solutions | 2 | 2008 | 18 | 0.460 |
Why?
|
| Macrophages | 5 | 2025 | 664 | 0.460 |
Why?
|
| Acute Kidney Injury | 5 | 2022 | 702 | 0.450 |
Why?
|
| Acute Disease | 12 | 2022 | 1154 | 0.450 |
Why?
|
| United States | 37 | 2022 | 12002 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2025 | 2063 | 0.440 |
Why?
|
| Monitoring, Intraoperative | 4 | 2011 | 126 | 0.440 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 566 | 0.440 |
Why?
|
| Brachiocephalic Trunk | 3 | 2017 | 35 | 0.430 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 243 | 0.430 |
Why?
|
| Young Adult | 24 | 2026 | 10037 | 0.430 |
Why?
|
| Catheterization | 3 | 2022 | 224 | 0.430 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1936 | 0.420 |
Why?
|
| Chemistry, Clinical | 1 | 2014 | 10 | 0.420 |
Why?
|
| Medical Oncology | 1 | 2016 | 243 | 0.410 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2014 | 38 | 0.410 |
Why?
|
| Dilatation, Pathologic | 4 | 2021 | 74 | 0.410 |
Why?
|
| Muscle Proteins | 1 | 2017 | 403 | 0.410 |
Why?
|
| Adipokines | 8 | 2025 | 119 | 0.410 |
Why?
|
| Cell Differentiation | 3 | 2021 | 1914 | 0.400 |
Why?
|
| Adolescent | 37 | 2026 | 20889 | 0.400 |
Why?
|
| Survival Analysis | 14 | 2019 | 1481 | 0.400 |
Why?
|
| Vascular Calcification | 1 | 2014 | 70 | 0.400 |
Why?
|
| Mutation | 10 | 2022 | 6064 | 0.400 |
Why?
|
| Spinal Cord | 4 | 2021 | 255 | 0.400 |
Why?
|
| Databases, Factual | 11 | 2025 | 1234 | 0.400 |
Why?
|
| Turner Syndrome | 3 | 2020 | 44 | 0.400 |
Why?
|
| Societies, Medical | 5 | 2019 | 792 | 0.390 |
Why?
|
| Hypothermia, Induced | 4 | 2016 | 172 | 0.390 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 484 | 0.380 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2012 | 10 | 0.380 |
Why?
|
| Genome-Wide Association Study | 5 | 2023 | 1829 | 0.370 |
Why?
|
| Coronary Artery Disease | 6 | 2020 | 890 | 0.370 |
Why?
|
| ADAM Proteins | 1 | 2012 | 79 | 0.370 |
Why?
|
| Receptor, Notch1 | 1 | 2012 | 78 | 0.370 |
Why?
|
| Phenotype | 11 | 2025 | 4459 | 0.360 |
Why?
|
| Elastic Tissue | 3 | 2020 | 18 | 0.360 |
Why?
|
| Hemorrhage | 2 | 2013 | 485 | 0.350 |
Why?
|
| Oxygen | 3 | 2011 | 548 | 0.350 |
Why?
|
| Vascular Grafting | 1 | 2012 | 51 | 0.350 |
Why?
|
| Self Concept | 1 | 2012 | 156 | 0.340 |
Why?
|
| Chronic Disease | 11 | 2024 | 1243 | 0.340 |
Why?
|
| Veterans | 11 | 2023 | 1756 | 0.330 |
Why?
|
| Apoptosis | 7 | 2021 | 1825 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 143 | 0.330 |
Why?
|
| Mammary Arteries | 2 | 2010 | 30 | 0.330 |
Why?
|
| Vascular Fistula | 3 | 2020 | 26 | 0.330 |
Why?
|
| Funnel Chest | 2 | 2012 | 33 | 0.320 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 4 | 2016 | 41 | 0.320 |
Why?
|
| Heart Defects, Congenital | 4 | 2021 | 1879 | 0.320 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 225 | 0.320 |
Why?
|
| Perfusion | 5 | 2016 | 209 | 0.320 |
Why?
|
| Endocarditis | 3 | 2018 | 102 | 0.310 |
Why?
|
| Cardiac Catheterization | 1 | 2014 | 631 | 0.310 |
Why?
|
| Logistic Models | 17 | 2024 | 1796 | 0.310 |
Why?
|
| Oximetry | 1 | 2011 | 176 | 0.300 |
Why?
|
| Cardiopulmonary Bypass | 6 | 2022 | 357 | 0.300 |
Why?
|
| Age Factors | 11 | 2021 | 2822 | 0.300 |
Why?
|
| Cardiovascular Diseases | 7 | 2020 | 2110 | 0.300 |
Why?
|
| Endothelium, Vascular | 3 | 2025 | 468 | 0.300 |
Why?
|
| Brain Ischemia | 1 | 2012 | 266 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 850 | 0.300 |
Why?
|
| Treatment Failure | 2 | 2026 | 348 | 0.300 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 253 | 0.300 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 2290 | 0.300 |
Why?
|
| Prosthesis Design | 10 | 2019 | 626 | 0.300 |
Why?
|
| Length of Stay | 11 | 2019 | 1413 | 0.290 |
Why?
|
| Hospitals | 3 | 2022 | 434 | 0.290 |
Why?
|
| Severity of Illness Index | 10 | 2023 | 3038 | 0.290 |
Why?
|
| Renal Circulation | 1 | 2008 | 41 | 0.290 |
Why?
|
| Isotonic Solutions | 1 | 2008 | 40 | 0.290 |
Why?
|
| Anastomosis, Surgical | 3 | 2006 | 176 | 0.280 |
Why?
|
| Diet, High-Fat | 3 | 2021 | 268 | 0.280 |
Why?
|
| Texas | 12 | 2022 | 3663 | 0.280 |
Why?
|
| Atherosclerosis | 3 | 2020 | 948 | 0.270 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 288 | 0.270 |
Why?
|
| Hemostasis, Surgical | 2 | 2012 | 34 | 0.270 |
Why?
|
| Endothelial Cells | 6 | 2021 | 520 | 0.270 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 1376 | 0.270 |
Why?
|
| Internship and Residency | 6 | 2020 | 1220 | 0.270 |
Why?
|
| Phrenic Nerve | 1 | 2007 | 10 | 0.270 |
Why?
|
| Neural Conduction | 1 | 2007 | 82 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2021 | 2827 | 0.260 |
Why?
|
| Resorcinols | 1 | 2007 | 7 | 0.260 |
Why?
|
| Gelatin | 1 | 2007 | 16 | 0.260 |
Why?
|
| Postoperative Care | 4 | 2020 | 294 | 0.260 |
Why?
|
| Sex Factors | 7 | 2025 | 1348 | 0.260 |
Why?
|
| Hospitals, Veterans | 6 | 2012 | 335 | 0.250 |
Why?
|
| Vertebral Artery | 1 | 2007 | 18 | 0.250 |
Why?
|
| Formaldehyde | 1 | 2007 | 49 | 0.250 |
Why?
|
| Endocarditis, Bacterial | 2 | 2018 | 127 | 0.250 |
Why?
|
| Mitral Valve | 2 | 2019 | 245 | 0.250 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2007 | 33 | 0.250 |
Why?
|
| Glutaral | 2 | 2007 | 8 | 0.250 |
Why?
|
| Vocal Cord Paralysis | 2 | 2018 | 68 | 0.250 |
Why?
|
| Incidence | 12 | 2020 | 3338 | 0.250 |
Why?
|
| Hematoma | 2 | 2020 | 85 | 0.240 |
Why?
|
| Heart Valve Prosthesis | 4 | 2011 | 303 | 0.240 |
Why?
|
| Microcirculation | 1 | 2006 | 104 | 0.240 |
Why?
|
| Odds Ratio | 8 | 2017 | 1208 | 0.230 |
Why?
|
| ADAMTS4 Protein | 2 | 2017 | 9 | 0.230 |
Why?
|
| Physicians | 1 | 2012 | 628 | 0.230 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2020 | 158 | 0.230 |
Why?
|
| Propensity Score | 4 | 2023 | 271 | 0.230 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 205 | 0.230 |
Why?
|
| Probability | 6 | 2009 | 305 | 0.220 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2025 | 15 | 0.220 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 1027 | 0.220 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2025 | 35 | 0.220 |
Why?
|
| Palmitic Acid | 3 | 2017 | 27 | 0.220 |
Why?
|
| Cohort Studies | 14 | 2019 | 5049 | 0.220 |
Why?
|
| Mutation, Missense | 3 | 2019 | 920 | 0.210 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 647 | 0.210 |
Why?
|
| Aneurysm, Ruptured | 2 | 2003 | 36 | 0.210 |
Why?
|
| Cerebrovascular Disorders | 2 | 2013 | 111 | 0.210 |
Why?
|
| Mesenteric Arteries | 1 | 2004 | 50 | 0.210 |
Why?
|
| Chi-Square Distribution | 10 | 2016 | 562 | 0.210 |
Why?
|
| Renal Artery Obstruction | 1 | 2004 | 39 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 1284 | 0.210 |
Why?
|
| Kidney Diseases | 1 | 2008 | 474 | 0.210 |
Why?
|
| Blood Transfusion | 3 | 2022 | 293 | 0.200 |
Why?
|
| Forkhead Transcription Factors | 3 | 2012 | 372 | 0.200 |
Why?
|
| Cerebrovascular Circulation | 4 | 2013 | 481 | 0.200 |
Why?
|
| Renal Dialysis | 4 | 2022 | 948 | 0.200 |
Why?
|
| Indenes | 2 | 2020 | 10 | 0.200 |
Why?
|
| Swine | 5 | 2009 | 1184 | 0.190 |
Why?
|
| Needles | 2 | 2005 | 48 | 0.190 |
Why?
|
| Computational Biology | 2 | 2026 | 861 | 0.190 |
Why?
|
| Furans | 2 | 2020 | 28 | 0.190 |
Why?
|
| Procollagen-Proline Dioxygenase | 3 | 2008 | 32 | 0.190 |
Why?
|
| Membrane Proteins | 3 | 2021 | 1590 | 0.190 |
Why?
|
| Genotype | 4 | 2021 | 2590 | 0.190 |
Why?
|
| Cerebrospinal Fluid | 4 | 2013 | 99 | 0.190 |
Why?
|
| Collagen | 2 | 2022 | 274 | 0.190 |
Why?
|
| Proportional Hazards Models | 10 | 2016 | 1404 | 0.180 |
Why?
|
| Morbidity | 2 | 2021 | 256 | 0.180 |
Why?
|
| Biomechanical Phenomena | 2 | 2017 | 279 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 2332 | 0.180 |
Why?
|
| Hemodynamics | 4 | 2020 | 811 | 0.180 |
Why?
|
| Exome | 3 | 2026 | 1061 | 0.180 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2021 | 124 | 0.180 |
Why?
|
| Serum Albumin, Bovine | 1 | 2002 | 37 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2025 | 280 | 0.180 |
Why?
|
| Comorbidity | 7 | 2012 | 1589 | 0.180 |
Why?
|
| Fibrillins | 5 | 2015 | 27 | 0.180 |
Why?
|
| Proteolysis | 3 | 2019 | 201 | 0.180 |
Why?
|
| Aneurysm, Infected | 1 | 2022 | 23 | 0.180 |
Why?
|
| Prognosis | 7 | 2019 | 4866 | 0.180 |
Why?
|
| Medicine | 1 | 2023 | 99 | 0.180 |
Why?
|
| Pneumonectomy | 2 | 2014 | 154 | 0.180 |
Why?
|
| Esophageal Fistula | 2 | 2000 | 14 | 0.170 |
Why?
|
| Body Temperature | 1 | 2002 | 126 | 0.170 |
Why?
|
| Peer Review | 1 | 2021 | 34 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2021 | 194 | 0.170 |
Why?
|
| Gasoline | 1 | 2021 | 4 | 0.170 |
Why?
|
| Brain Damage, Chronic | 1 | 2001 | 27 | 0.170 |
Why?
|
| S100 Proteins | 1 | 2001 | 40 | 0.170 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 999 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 421 | 0.170 |
Why?
|
| Renal Insufficiency | 6 | 2016 | 256 | 0.170 |
Why?
|
| Transcriptome | 3 | 2025 | 1097 | 0.170 |
Why?
|
| Sample Size | 1 | 2021 | 84 | 0.170 |
Why?
|
| Dissection | 1 | 2021 | 55 | 0.170 |
Why?
|
| Cultural Diversity | 1 | 2021 | 81 | 0.160 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2020 | 9 | 0.160 |
Why?
|
| Cell Division | 1 | 2002 | 718 | 0.160 |
Why?
|
| Research Design | 1 | 2025 | 714 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2020 | 297 | 0.160 |
Why?
|
| Academic Medical Centers | 5 | 2020 | 320 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2021 | 56 | 0.160 |
Why?
|
| Drainage | 5 | 2013 | 246 | 0.160 |
Why?
|
| Unfolded Protein Response | 1 | 2020 | 66 | 0.160 |
Why?
|
| Intraoperative Care | 6 | 2010 | 123 | 0.160 |
Why?
|
| THP-1 Cells | 1 | 2020 | 22 | 0.160 |
Why?
|
| Intestinal Fistula | 1 | 2020 | 22 | 0.160 |
Why?
|
| Cell Transdifferentiation | 1 | 2020 | 57 | 0.160 |
Why?
|
| Actins | 2 | 2015 | 320 | 0.160 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 737 | 0.160 |
Why?
|
| Organizational Objectives | 1 | 2020 | 34 | 0.160 |
Why?
|
| Regional Blood Flow | 3 | 2011 | 191 | 0.160 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2009 | 73 | 0.160 |
Why?
|
| Seasons | 3 | 2016 | 335 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 225 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 198 | 0.150 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 265 | 0.150 |
Why?
|
| Cytosol | 1 | 2019 | 135 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2012 | 38 | 0.150 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2019 | 15 | 0.150 |
Why?
|
| Splenectomy | 1 | 2019 | 61 | 0.150 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 99 | 0.150 |
Why?
|
| Thioredoxins | 2 | 2009 | 28 | 0.150 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2011 | 159 | 0.150 |
Why?
|
| Elective Surgical Procedures | 5 | 2017 | 161 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 2080 | 0.150 |
Why?
|
| Asia | 1 | 2019 | 123 | 0.150 |
Why?
|
| Professional Competence | 1 | 2020 | 97 | 0.150 |
Why?
|
| Coculture Techniques | 2 | 2017 | 229 | 0.150 |
Why?
|
| Poverty | 1 | 2022 | 462 | 0.140 |
Why?
|
| Analysis of Variance | 4 | 2012 | 927 | 0.140 |
Why?
|
| Smad4 Protein | 1 | 2019 | 59 | 0.140 |
Why?
|
| Models, Statistical | 3 | 2010 | 483 | 0.140 |
Why?
|
| Pericarditis, Constrictive | 1 | 1998 | 6 | 0.140 |
Why?
|
| Anesthesiologists | 3 | 2022 | 43 | 0.140 |
Why?
|
| Research Personnel | 1 | 2020 | 139 | 0.140 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 316 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 151 | 0.140 |
Why?
|
| Wound Healing | 1 | 2002 | 486 | 0.140 |
Why?
|
| Heart Injuries | 1 | 1998 | 48 | 0.140 |
Why?
|
| Embolism | 1 | 1998 | 38 | 0.140 |
Why?
|
| Autoimmunity | 1 | 2019 | 175 | 0.140 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 92 | 0.130 |
Why?
|
| Versicans | 1 | 2017 | 15 | 0.130 |
Why?
|
| Cholesterol | 1 | 2020 | 538 | 0.130 |
Why?
|
| American Heart Association | 1 | 2020 | 339 | 0.130 |
Why?
|
| Random Allocation | 1 | 2018 | 409 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2020 | 217 | 0.130 |
Why?
|
| Proteomics | 1 | 2022 | 616 | 0.130 |
Why?
|
| Manuscripts, Medical as Topic | 1 | 2017 | 8 | 0.130 |
Why?
|
| Antimicrobial Stewardship | 1 | 2019 | 88 | 0.130 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2017 | 18 | 0.130 |
Why?
|
| Constriction, Pathologic | 3 | 2020 | 222 | 0.130 |
Why?
|
| Europe | 3 | 2016 | 363 | 0.130 |
Why?
|
| Glyburide | 1 | 2017 | 22 | 0.130 |
Why?
|
| Chronobiology Phenomena | 1 | 2016 | 1 | 0.130 |
Why?
|
| Laryngoplasty | 1 | 2017 | 28 | 0.130 |
Why?
|
| Foreign Bodies | 1 | 1998 | 97 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 516 | 0.130 |
Why?
|
| Quality Control | 1 | 2017 | 116 | 0.130 |
Why?
|
| Spinal Cord Diseases | 2 | 2007 | 32 | 0.130 |
Why?
|
| Peer Review, Research | 1 | 2017 | 45 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 339 | 0.130 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 96 | 0.120 |
Why?
|
| Coronary Disease | 2 | 2012 | 626 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1999 | 178 | 0.120 |
Why?
|
| Child | 15 | 2022 | 26263 | 0.120 |
Why?
|
| Radiography | 4 | 2016 | 741 | 0.120 |
Why?
|
| Iowa | 1 | 2016 | 13 | 0.120 |
Why?
|
| Radiation Chimera | 1 | 2016 | 16 | 0.120 |
Why?
|
| Phosphorylation | 4 | 2017 | 1571 | 0.120 |
Why?
|
| Pericytes | 1 | 2016 | 18 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2017 | 1208 | 0.120 |
Why?
|
| Tracheostomy | 1 | 2019 | 211 | 0.120 |
Why?
|
| Peptide Fragments | 2 | 2019 | 686 | 0.120 |
Why?
|
| Patient Discharge | 4 | 2021 | 514 | 0.120 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2016 | 35 | 0.120 |
Why?
|
| RNA, Small Interfering | 4 | 2018 | 662 | 0.120 |
Why?
|
| Reactive Oxygen Species | 2 | 2009 | 523 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2019 | 436 | 0.120 |
Why?
|
| Collagen Type III | 2 | 2025 | 23 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 500 | 0.120 |
Why?
|
| Cause of Death | 3 | 2002 | 503 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1122 | 0.120 |
Why?
|
| Spinal Cord Injuries | 1 | 1999 | 271 | 0.120 |
Why?
|
| Up-Regulation | 6 | 2009 | 826 | 0.120 |
Why?
|
| Heart Conduction System | 1 | 2017 | 163 | 0.120 |
Why?
|
| Intraoperative Complications | 4 | 2018 | 153 | 0.120 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2016 | 110 | 0.120 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 154 | 0.120 |
Why?
|
| Peripheral Arterial Disease | 1 | 2020 | 324 | 0.110 |
Why?
|
| Sex Distribution | 3 | 2020 | 318 | 0.110 |
Why?
|
| Family | 1 | 2019 | 587 | 0.110 |
Why?
|
| Intracranial Aneurysm | 1 | 2016 | 88 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2011 | 1690 | 0.110 |
Why?
|
| Peptide Hormones | 1 | 2016 | 68 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1592 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2026 | 1554 | 0.110 |
Why?
|
| Organ Size | 1 | 2016 | 408 | 0.110 |
Why?
|
| Pneumonia | 1 | 2019 | 340 | 0.110 |
Why?
|
| Genes, Reporter | 1 | 2016 | 340 | 0.110 |
Why?
|
| Gene Expression | 3 | 2021 | 1482 | 0.110 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2012 | 99 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 638 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 542 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2016 | 262 | 0.110 |
Why?
|
| Inflammation | 3 | 2021 | 1481 | 0.110 |
Why?
|
| Fasting | 1 | 2016 | 304 | 0.110 |
Why?
|
| Health Status Indicators | 2 | 2012 | 111 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2006 | 252 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2006 | 302 | 0.100 |
Why?
|
| Heterozygote | 1 | 2016 | 721 | 0.100 |
Why?
|
| Insulin | 3 | 2016 | 1146 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 335 | 0.100 |
Why?
|
| Obesity | 3 | 2017 | 2413 | 0.100 |
Why?
|
| Bronchial Fistula | 1 | 2014 | 24 | 0.100 |
Why?
|
| Biomarkers | 3 | 2014 | 3367 | 0.100 |
Why?
|
| Hospitals, Teaching | 2 | 2011 | 109 | 0.100 |
Why?
|
| Citric Acid | 1 | 2014 | 45 | 0.100 |
Why?
|
| Blood Specimen Collection | 1 | 2014 | 46 | 0.100 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 34 | 0.100 |
Why?
|
| Education, Medical, Graduate | 3 | 2020 | 552 | 0.100 |
Why?
|
| Glycosaminoglycans | 1 | 2013 | 43 | 0.100 |
Why?
|
| Gene Dosage | 2 | 2016 | 435 | 0.100 |
Why?
|
| Forecasting | 2 | 2013 | 352 | 0.100 |
Why?
|
| Mitral Valve Prolapse | 1 | 2013 | 34 | 0.100 |
Why?
|
| CD3 Complex | 1 | 2013 | 95 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2021 | 842 | 0.100 |
Why?
|
| Preoperative Care | 3 | 2020 | 358 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2009 | 161 | 0.100 |
Why?
|
| Heart-Assist Devices | 3 | 2011 | 1018 | 0.100 |
Why?
|
| Azides | 2 | 2023 | 11 | 0.100 |
Why?
|
| Myocytes, Cardiac | 1 | 2018 | 670 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 1879 | 0.100 |
Why?
|
| Deoxyglucose | 2 | 2023 | 41 | 0.100 |
Why?
|
| Aortitis | 1 | 2012 | 6 | 0.100 |
Why?
|
| ADAMTS1 Protein | 1 | 2012 | 15 | 0.100 |
Why?
|
| Protein Binding | 2 | 2017 | 1652 | 0.090 |
Why?
|
| Enzyme Induction | 1 | 2012 | 92 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2012 | 646 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 818 | 0.090 |
Why?
|
| Bioprosthesis | 2 | 2011 | 110 | 0.090 |
Why?
|
| Antigens, CD34 | 1 | 2012 | 97 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 386 | 0.090 |
Why?
|
| Heparin | 1 | 2014 | 206 | 0.090 |
Why?
|
| Antigens, Surface | 1 | 2012 | 112 | 0.090 |
Why?
|
| Journal Impact Factor | 1 | 2012 | 26 | 0.090 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 50 | 0.090 |
Why?
|
| Parathyroid Neoplasms | 1 | 2012 | 20 | 0.090 |
Why?
|
| Cell Movement | 1 | 2016 | 875 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 209 | 0.090 |
Why?
|
| Parathyroid Glands | 1 | 2012 | 26 | 0.090 |
Why?
|
| RNA, Messenger | 7 | 2022 | 2547 | 0.090 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 51 | 0.090 |
Why?
|
| Career Mobility | 1 | 2012 | 52 | 0.090 |
Why?
|
| Compliance | 2 | 2009 | 17 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 63 | 0.090 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2010 | 86 | 0.090 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2012 | 38 | 0.090 |
Why?
|
| Child, Preschool | 10 | 2020 | 15045 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2013 | 409 | 0.090 |
Why?
|
| Reference Values | 2 | 2012 | 673 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2017 | 974 | 0.090 |
Why?
|
| Angiography | 2 | 2014 | 180 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 411 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 322 | 0.090 |
Why?
|
| Mitochondria | 1 | 2017 | 776 | 0.090 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 110 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 680 | 0.080 |
Why?
|
| Hypoalbuminemia | 1 | 2011 | 16 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 564 | 0.080 |
Why?
|
| Hypertension | 3 | 2016 | 1352 | 0.080 |
Why?
|
| Echocardiography | 6 | 2017 | 1132 | 0.080 |
Why?
|
| Stem Cells | 1 | 2016 | 704 | 0.080 |
Why?
|
| Pedigree | 4 | 2023 | 1670 | 0.080 |
Why?
|
| Health Resources | 1 | 2012 | 130 | 0.080 |
Why?
|
| Forced Expiratory Volume | 2 | 2023 | 178 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2011 | 101 | 0.080 |
Why?
|
| Adenoma | 1 | 2012 | 142 | 0.080 |
Why?
|
| Mentors | 1 | 2012 | 169 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2011 | 148 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 359 | 0.080 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2011 | 79 | 0.080 |
Why?
|
| Chromosome Duplication | 1 | 2011 | 146 | 0.080 |
Why?
|
| Endarterectomy, Carotid | 1 | 2011 | 75 | 0.080 |
Why?
|
| Transplantation, Homologous | 3 | 2002 | 668 | 0.080 |
Why?
|
| Uniparental Disomy | 1 | 2010 | 42 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 1320 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2012 | 357 | 0.080 |
Why?
|
| Arteries | 2 | 2023 | 209 | 0.080 |
Why?
|
| Hypotension | 1 | 2012 | 187 | 0.080 |
Why?
|
| Angioplasty | 2 | 2008 | 63 | 0.080 |
Why?
|
| Heart Diseases | 2 | 2009 | 496 | 0.080 |
Why?
|
| Community Health Planning | 1 | 2009 | 6 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2896 | 0.080 |
Why?
|
| Hospitalization | 1 | 2019 | 1942 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 308 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2012 | 294 | 0.080 |
Why?
|
| Genetic Loci | 1 | 2011 | 353 | 0.080 |
Why?
|
| Chromatin | 2 | 2023 | 499 | 0.080 |
Why?
|
| Age Distribution | 2 | 2008 | 421 | 0.080 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2009 | 42 | 0.080 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 231 | 0.070 |
Why?
|
| Glucose | 2 | 2016 | 851 | 0.070 |
Why?
|
| Amputees | 1 | 2009 | 9 | 0.070 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 29 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2014 | 601 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 911 | 0.070 |
Why?
|
| Work Schedule Tolerance | 1 | 2009 | 40 | 0.070 |
Why?
|
| Anesthesia | 1 | 2011 | 208 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2007 | 193 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 1278 | 0.070 |
Why?
|
| Elasticity | 1 | 2009 | 97 | 0.070 |
Why?
|
| Quality of Health Care | 2 | 2009 | 411 | 0.070 |
Why?
|
| Emergency Treatment | 2 | 2016 | 78 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2009 | 41 | 0.070 |
Why?
|
| Thorax | 2 | 2006 | 62 | 0.070 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2008 | 15 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2006 | 186 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2013 | 378 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 618 | 0.070 |
Why?
|
| Doxycycline | 1 | 2009 | 112 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 587 | 0.070 |
Why?
|
| Clinical Competence | 3 | 2011 | 1045 | 0.070 |
Why?
|
| Octamer Transcription Factors | 1 | 2008 | 9 | 0.070 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2008 | 18 | 0.070 |
Why?
|
| Quality of Life | 2 | 2016 | 2072 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2010 | 517 | 0.070 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 135 | 0.070 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 170 | 0.070 |
Why?
|
| Coronary Restenosis | 1 | 2008 | 23 | 0.070 |
Why?
|
| Surgery Department, Hospital | 1 | 2008 | 20 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 205 | 0.070 |
Why?
|
| Subclavian Artery | 1 | 2008 | 65 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 3812 | 0.070 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2007 | 12 | 0.060 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2007 | 8 | 0.060 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 28 | 0.060 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 3 | 2013 | 29 | 0.060 |
Why?
|
| Albumins | 1 | 2007 | 87 | 0.060 |
Why?
|
| Sus scrofa | 1 | 2007 | 112 | 0.060 |
Why?
|
| Prevalence | 4 | 2017 | 2692 | 0.060 |
Why?
|
| Necrosis | 1 | 2007 | 193 | 0.060 |
Why?
|
| Constriction | 3 | 2016 | 46 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 242 | 0.060 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 22 | 0.060 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2017 | 47 | 0.060 |
Why?
|
| Oxyhemoglobins | 1 | 2006 | 25 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2009 | 374 | 0.060 |
Why?
|
| Cyclonic Storms | 1 | 2008 | 82 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 24 | 0.060 |
Why?
|
| Ligation | 1 | 2006 | 134 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 560 | 0.060 |
Why?
|
| Cicatrix | 1 | 2007 | 124 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2007 | 267 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 112 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2007 | 216 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 902 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2006 | 57 | 0.060 |
Why?
|
| RNA Interference | 2 | 2018 | 491 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2006 | 110 | 0.060 |
Why?
|
| Shock, Cardiogenic | 1 | 2008 | 177 | 0.060 |
Why?
|
| Brain | 3 | 2003 | 3167 | 0.060 |
Why?
|
| Resistin | 1 | 2006 | 30 | 0.060 |
Why?
|
| Thrombosis | 1 | 2011 | 498 | 0.060 |
Why?
|
| Polyethylene Terephthalates | 1 | 2005 | 22 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2021 | 321 | 0.060 |
Why?
|
| Decision Making | 1 | 2011 | 714 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 326 | 0.060 |
Why?
|
| Linear Models | 3 | 2013 | 687 | 0.060 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 116 | 0.060 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 1 | 2025 | 4 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2006 | 285 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2005 | 11 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2011 | 1344 | 0.060 |
Why?
|
| Angiopoietin-2 | 1 | 2005 | 11 | 0.060 |
Why?
|
| Neural Crest | 1 | 2025 | 51 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 258 | 0.050 |
Why?
|
| Hindlimb | 1 | 2005 | 72 | 0.050 |
Why?
|
| Particle Size | 1 | 2025 | 135 | 0.050 |
Why?
|
| Heart Rate | 1 | 2007 | 576 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2026 | 729 | 0.050 |
Why?
|
| Social Class | 2 | 2020 | 214 | 0.050 |
Why?
|
| Histones | 1 | 2008 | 541 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 533 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2009 | 996 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2008 | 565 | 0.050 |
Why?
|
| HIV | 1 | 2005 | 174 | 0.050 |
Why?
|
| Skin Diseases, Genetic | 1 | 2023 | 21 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 196 | 0.050 |
Why?
|
| Spirometry | 1 | 2023 | 92 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2025 | 344 | 0.050 |
Why?
|
| Hospital Departments | 1 | 2023 | 15 | 0.050 |
Why?
|
| Joint Instability | 1 | 2023 | 55 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 787 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 324 | 0.050 |
Why?
|
| Consensus | 2 | 2017 | 524 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 224 | 0.050 |
Why?
|
| Syndrome | 2 | 2020 | 1156 | 0.050 |
Why?
|
| Patient Selection | 2 | 2011 | 724 | 0.050 |
Why?
|
| Foreign-Body Migration | 1 | 2003 | 64 | 0.050 |
Why?
|
| Vascular Malformations | 1 | 2023 | 103 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 181 | 0.050 |
Why?
|
| Hospital Bed Capacity | 2 | 2012 | 29 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 1546 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2006 | 1440 | 0.050 |
Why?
|
| Transforming Growth Factors | 1 | 2022 | 17 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 964 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2023 | 112 | 0.040 |
Why?
|
| Income | 1 | 2022 | 138 | 0.040 |
Why?
|
| Viscera | 1 | 2002 | 56 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 616 | 0.040 |
Why?
|
| Hypothermia | 1 | 2002 | 61 | 0.040 |
Why?
|
| Neointima | 1 | 2021 | 48 | 0.040 |
Why?
|
| Subarachnoid Space | 1 | 2001 | 23 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2005 | 398 | 0.040 |
Why?
|
| Respiratory Tract Fistula | 1 | 2001 | 15 | 0.040 |
Why?
|
| Trachea | 1 | 2003 | 207 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3752 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2016 | 3465 | 0.040 |
Why?
|
| Catheters | 1 | 2021 | 78 | 0.040 |
Why?
|
| Pleura | 1 | 2001 | 27 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1363 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2008 | 815 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2001 | 84 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 1206 | 0.040 |
Why?
|
| Mediastinal Cyst | 1 | 2000 | 8 | 0.040 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2020 | 34 | 0.040 |
Why?
|
| Brachiocephalic Veins | 1 | 2000 | 12 | 0.040 |
Why?
|
| Recurrence | 2 | 2002 | 1483 | 0.040 |
Why?
|
| Transfection | 2 | 2017 | 961 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2020 | 36 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2020 | 54 | 0.040 |
Why?
|
| Inpatients | 2 | 2017 | 561 | 0.040 |
Why?
|
| Histone Demethylases | 1 | 2020 | 41 | 0.040 |
Why?
|
| Curriculum | 2 | 2020 | 792 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2020 | 152 | 0.040 |
Why?
|
| Receptors, Angiotensin | 1 | 2020 | 20 | 0.040 |
Why?
|
| Cell Line | 2 | 2020 | 2553 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2020 | 106 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 157 | 0.040 |
Why?
|
| Ion Channels | 1 | 2021 | 195 | 0.040 |
Why?
|
| ADAMTS5 Protein | 1 | 2019 | 4 | 0.040 |
Why?
|
| Aggrecans | 1 | 2019 | 6 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2020 | 111 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 128 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2005 | 711 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 61 | 0.040 |
Why?
|
| Splenic Diseases | 1 | 2019 | 28 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2019 | 78 | 0.040 |
Why?
|
| Leukocyte Elastase | 1 | 2019 | 20 | 0.040 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2019 | 14 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 148 | 0.040 |
Why?
|
| Organizational Culture | 1 | 2020 | 95 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2026 | 1105 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2019 | 81 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2010 | 276 | 0.040 |
Why?
|
| Splenic Artery | 1 | 1999 | 22 | 0.040 |
Why?
|
| Smokers | 1 | 2019 | 47 | 0.040 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2020 | 150 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1605 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2000 | 148 | 0.040 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2018 | 14 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 502 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 122 | 0.040 |
Why?
|
| Family Health | 2 | 2009 | 240 | 0.040 |
Why?
|
| Spleen | 1 | 2019 | 258 | 0.040 |
Why?
|
| Pericardiectomy | 1 | 1998 | 9 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 157 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2018 | 99 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 174 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 42 | 0.030 |
Why?
|
| Sternum | 1 | 1998 | 51 | 0.030 |
Why?
|
| Infant | 3 | 2019 | 13318 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 237 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2018 | 149 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 756 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2018 | 271 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2019 | 240 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2010 | 777 | 0.030 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 13 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2000 | 450 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 404 | 0.030 |
Why?
|
| Dogs | 1 | 2018 | 615 | 0.030 |
Why?
|
| Paresis | 1 | 1997 | 32 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1998 | 103 | 0.030 |
Why?
|
| Insulin Resistance | 2 | 2017 | 686 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2021 | 695 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1999 | 363 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1999 | 247 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2017 | 55 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 109 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 1997 | 51 | 0.030 |
Why?
|
| Abscess | 1 | 1998 | 137 | 0.030 |
Why?
|
| Nucleotidyltransferases | 1 | 2017 | 47 | 0.030 |
Why?
|
| DNA Primers | 2 | 2009 | 600 | 0.030 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2016 | 6 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2019 | 543 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 125 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2017 | 113 | 0.030 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2016 | 22 | 0.030 |
Why?
|
| Plasmids | 2 | 2009 | 444 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2012 | 525 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1263 | 0.030 |
Why?
|
| Emergencies | 2 | 2011 | 171 | 0.030 |
Why?
|
| Genes, X-Linked | 1 | 2016 | 59 | 0.030 |
Why?
|
| Activating Transcription Factor 2 | 2 | 2006 | 16 | 0.030 |
Why?
|
| Progeria | 1 | 2016 | 17 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 172 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 160 | 0.030 |
Why?
|
| Disease | 1 | 1997 | 121 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2016 | 74 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2016 | 48 | 0.030 |
Why?
|
| Arterio-Arterial Fistula | 1 | 1995 | 10 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 1535 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2017 | 232 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2006 | 223 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2016 | 97 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 158 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2016 | 221 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2016 | 140 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 576 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2009 | 749 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1997 | 394 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 316 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2016 | 583 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2007 | 1014 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 245 | 0.030 |
Why?
|
| Colon | 1 | 1997 | 366 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 265 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2017 | 498 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2018 | 858 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 1076 | 0.030 |
Why?
|
| Fibrillin-2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2016 | 252 | 0.030 |
Why?
|
| Pregnancy | 2 | 2016 | 7459 | 0.030 |
Why?
|
| Calcium | 1 | 2018 | 1009 | 0.030 |
Why?
|
| Body Surface Area | 1 | 1993 | 36 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2016 | 767 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 319 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1998 | 561 | 0.020 |
Why?
|
| Binding Sites | 2 | 2006 | 1134 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 555 | 0.020 |
Why?
|
| Heart Failure | 3 | 2009 | 2327 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1620 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 643 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 59 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2016 | 2402 | 0.020 |
Why?
|
| Renal Artery | 2 | 2008 | 73 | 0.020 |
Why?
|
| Publications | 1 | 2012 | 36 | 0.020 |
Why?
|
| Lung Injury | 1 | 2014 | 126 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2393 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 1995 | 437 | 0.020 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2011 | 17 | 0.020 |
Why?
|
| Evoked Potentials, Motor | 1 | 2011 | 28 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 2730 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2012 | 191 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2011 | 74 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2011 | 63 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 73 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2011 | 78 | 0.020 |
Why?
|
| Hospital Charges | 1 | 2010 | 70 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2010 | 118 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2010 | 145 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2011 | 106 | 0.020 |
Why?
|
| Cardiac Output, Low | 1 | 2010 | 58 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2010 | 180 | 0.020 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2009 | 18 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2009 | 90 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 303 | 0.020 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2009 | 31 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 214 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2009 | 103 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2010 | 80 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 821 | 0.020 |
Why?
|
| Ribonucleotides | 1 | 2009 | 31 | 0.020 |
Why?
|
| Mexico | 1 | 2009 | 190 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2010 | 187 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 358 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 3727 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 87 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 246 | 0.020 |
Why?
|
| Risk Management | 1 | 2009 | 67 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 293 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 187 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2009 | 330 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 1783 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 118 | 0.020 |
Why?
|
| Protein Deglycase DJ-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2008 | 33 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Teaching | 1 | 2009 | 196 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 129 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2008 | 63 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 612 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 53 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 39 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 423 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 191 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 444 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1212 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 136 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 992 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 130 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 759 | 0.020 |
Why?
|
| Workload | 1 | 2008 | 151 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2006 | 21 | 0.020 |
Why?
|
| Linoleic Acid | 1 | 2006 | 20 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2008 | 184 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2010 | 718 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 83 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 54 | 0.010 |
Why?
|
| Aging | 1 | 1993 | 1238 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2006 | 121 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 88 | 0.010 |
Why?
|
| Frail Elderly | 1 | 2007 | 107 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2007 | 355 | 0.010 |
Why?
|
| Luciferases | 1 | 2006 | 126 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2012 | 1701 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 106 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2009 | 1061 | 0.010 |
Why?
|
| Response Elements | 1 | 2006 | 102 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 305 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 165 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 152 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 498 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1485 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2006 | 229 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 142 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 586 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2006 | 293 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 414 | 0.010 |
Why?
|
| Systole | 1 | 2005 | 195 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 688 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 155 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 573 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 405 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 2003 | 178 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 2461 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 618 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 4058 | 0.010 |
Why?
|
| Thoracostomy | 1 | 2001 | 26 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 892 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2003 | 181 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1375 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 930 | 0.010 |
Why?
|
| Venous Insufficiency | 1 | 2000 | 6 | 0.010 |
Why?
|
| Decompression, Surgical | 1 | 2001 | 83 | 0.010 |
Why?
|
| Spinal Fractures | 1 | 2001 | 48 | 0.010 |
Why?
|
| Jugular Veins | 1 | 2000 | 71 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 1023 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1999 | 78 | 0.010 |
Why?
|
| Debridement | 1 | 1999 | 94 | 0.010 |
Why?
|
| Colectomy | 1 | 1997 | 89 | 0.010 |
Why?
|
| Equipment Design | 1 | 1998 | 509 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1993 | 760 | 0.010 |
Why?
|